Literature DB >> 24114606

Long-term follow-up in infantile-onset lambert-eaton myasthenic syndrome.

S Portaro1, D Parisi2, A Polizzi3, M Ruggieri4, F Andreetta5, P Bernasconi5, A Toscano2, C Rodolico6.   

Abstract

Lambert-Eaton myasthenic syndrome is a neuromuscular junction disorder characterized by proximal limb muscle weakness, fatigability, decreased deep-tendon reflexes, and autonomic symptoms. There are 2 forms of Lambert-Eaton myasthenic syndrome: one most frequently associated with small-cell lung cancer (P-Lambert-Eaton myasthenic syndrome) and the other that is a pure autoimmune form (NP-Lambert-Eaton myasthenic syndrome). Lambert-Eaton myasthenic syndrome is a very rare disorder in children younger than age 12 years. Herein, we report a 25-year-old man with NP-Lambert-Eaton myasthenic syndrome, which onset was at the age of 10 years. To date, this is the most long-term follow-up of NP-Lambert-Eaton myasthenic syndrome in childhood. In our patient, the only symptomatic treatment with 3,4-diaminopyridine phosphate has been sufficient to guarantee him a good quality of life. Our data remind physicians to keep in mind the diagnosis of Lambert-Eaton myasthenic syndrome in children with a proximal myopathic pattern and they confirm the specificity of compound muscle action potential incremental pattern after brief maximal effort in Lambert-Eaton myasthenic syndrome.
© The Author(s) 2013.

Entities:  

Keywords:  3,4-diaminopyridine phosphate; Lambert-Eaton syndrome; anti-voltage-gated calcium channel antibodies; proximal muscle weakness

Mesh:

Year:  2013        PMID: 24114606     DOI: 10.1177/0883073813499970

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  2 in total

1.  Lambert-Eaton myasthenic syndrome in a patient with small-cell lung cancer: A case report.

Authors:  Ran-Ran Zhang; Tao Han; Fang Guo; Zhao-Zhe Liu; Ya-Ling Han; Wei-Chi Chen; Yong-Ye Liu; Xiao-Dong Xie
Journal:  Oncol Lett       Date:  2015-07-08       Impact factor: 2.967

2.  Five years experience on 3,4-diaminopyridine phosphate in Lambert-Eaton syndrome: Case reports.

Authors:  Simona Portaro; Teresa Brizzi; Stefano Sinicropi; Alberto Cacciola; Maria Cristina De Cola; Alessia Bramanti; Demetrio Milardi; Antonino Lupica; Placido Bramanti; Antonio Toscano; Carmelo Rodolico
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.